Recruitment

Recruitment Status
Completed
Estimated Enrollment
90

Inclusion Criterias

Singleton pregnancies.
ASA (American Association of Anesthesiologists) class 1 or 2 patients.
Healthy pregnant patients with uncomplicated pregnancies:
Singleton pregnancies.
ASA (American Association of Anesthesiologists) class 1 or 2 patients.
Healthy pregnant patients with uncomplicated pregnancies:

Exclusion Criterias

Known uterine abnormality.
Known placental abnormality.
Known drug allergy to intravenous oxytocin.
...
Known uterine abnormality.
Known placental abnormality.
Known drug allergy to intravenous oxytocin.
ASA class 3 or 4 patients.
Significant medical or obstetric disease.

Summary

Conditions
Postpartum Hemorrhage
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Single Group Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 40 years
Gender
Only females

Description

Oxytocin (pitocin) is a drug commonly used in obstetric practice, and the drug effect is to increase the muscular tone of the uterus to reduce uterine bleeding after neonatal delivery. Pregnant patients undergoing elective (scheduled)Cesarean delivery routinely receive oxytocin after delivery of the...

Oxytocin (pitocin) is a drug commonly used in obstetric practice, and the drug effect is to increase the muscular tone of the uterus to reduce uterine bleeding after neonatal delivery. Pregnant patients undergoing elective (scheduled)Cesarean delivery routinely receive oxytocin after delivery of the baby. Post-delivery, oxytocin is commonly administered as an IV bolus and/or infusion. No previous studies have accurately assessed differences in oxytocin infusions after delivery in patients undergoing elective cesarean delivery. Thus the study aim is to investigate which infusion rate can optimally provide adequate maintenance of uterine tone during Cesarean delivery while being associated with minimal or no maternal side-effects.

Inclusion Criterias

Singleton pregnancies.
ASA (American Association of Anesthesiologists) class 1 or 2 patients.
Healthy pregnant patients with uncomplicated pregnancies:
Singleton pregnancies.
ASA (American Association of Anesthesiologists) class 1 or 2 patients.
Healthy pregnant patients with uncomplicated pregnancies:

Exclusion Criterias

Known uterine abnormality.
Known placental abnormality.
Known drug allergy to intravenous oxytocin.
...
Known uterine abnormality.
Known placental abnormality.
Known drug allergy to intravenous oxytocin.
ASA class 3 or 4 patients.
Significant medical or obstetric disease.

Locations

Stanford, California, 94305
Stanford, California, 94305

Tracking Information

NCT #
NCT01932060
Collaborators
Not Provided
Investigators
  • Principal Investigator: Alexander J Butwick, F.R.C.A. Stanford University
  • Alexander J Butwick, F.R.C.A. Stanford University